These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 24771603)

  • 1. Population pharmacometric analyses of eribulin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.
    Majid O; Gupta A; Reyderman L; Olivo M; Hussein Z
    J Clin Pharmacol; 2014 Oct; 54(10):1134-43. PubMed ID: 24771603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
    Scarpace SL
    Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.
    Aftimos P; Polastro L; Ameye L; Jungels C; Vakili J; Paesmans M; van den Eerenbeemt J; Buttice A; Gombos A; de Valeriola D; Gil T; Piccart-Gebhart M; Awada A
    Eur J Cancer; 2016 Jun; 60():117-24. PubMed ID: 27107326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancer.
    Chabot I; Zhao Q; Su Y
    Curr Med Res Opin; 2020 Dec; 36(12):2025-2036. PubMed ID: 33044090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eribulin mesylate.
    Jain S; Vahdat LT
    Clin Cancer Res; 2011 Nov; 17(21):6615-22. PubMed ID: 21859830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.
    Maeda S; Saimura M; Minami S; Kurashita K; Nishimura R; Kai Y; Yano H; Mashino K; Mitsuyama S; Shimokawa M; Tamura K;
    Breast; 2017 Apr; 32():66-72. PubMed ID: 28056400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer.
    Cortes J; Lorca R
    Future Oncol; 2011 Mar; 7(3):355-64. PubMed ID: 21375468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.
    Iizumi S; Shimoi T; Tsushita N; Bun S; Shimomura A; Noguchi E; Kodaira M; Yunokawa M; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
    BMC Cancer; 2017 Dec; 17(1):819. PubMed ID: 29202787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer.
    Twelves C; Cortes J; Vahdat LT; Wanders J; Akerele C; Kaufman PA
    Clin Breast Cancer; 2010 Apr; 10(2):160-3. PubMed ID: 20299316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.
    McBride A; Butler SK
    Am J Health Syst Pharm; 2012 May; 69(9):745-55. PubMed ID: 22517020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.
    Morgan RJ; Synold TW; Longmate JA; Quinn DI; Gandara D; Lenz HJ; Ruel C; Xi B; Lewis MD; Colevas AD; Doroshow J; Newman EM
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):897-907. PubMed ID: 26362045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer.
    Kashiwagi S; Asano Y; Goto W; Takada K; Takahashi K; Noda S; Takashima T; Onoda N; Tomita S; Ohsawa M; Hirakawa K; Ohira M
    PLoS One; 2017; 12(2):e0170634. PubMed ID: 28166544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eribulin mesylate for the treatment of breast cancer.
    Cigler T; Vahdat LT
    Expert Opin Pharmacother; 2010 Jun; 11(9):1587-93. PubMed ID: 20450446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.
    Park YH; Kim TY; Im YH; Lee KS; Park IH; Sohn J; Lee SH; Im SA; Kim JH; Kim SH; Lee SJ; Koh SJ; Lee KH; Choi YJ; Cho EK; Lee S; Kang SY; Seo JH; Kim SB; Jung KH
    Cancer Res Treat; 2017 Apr; 49(2):423-429. PubMed ID: 27488876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
    Vahdat LT; Pruitt B; Fabian CJ; Rivera RR; Smith DA; Tan-Chiu E; Wright J; Tan AR; Dacosta NA; Chuang E; Smith J; O'Shaughnessy J; Shuster DE; Meneses NL; Chandrawansa K; Fang F; Cole PE; Ashworth S; Blum JL
    J Clin Oncol; 2009 Jun; 27(18):2954-61. PubMed ID: 19349550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis.
    O'Shaughnessy J; Cortes J; Twelves C; Goldstein LJ; Alexis K; Xie R; Barrios C; Ueno T
    Sci Rep; 2020 Jul; 10(1):11203. PubMed ID: 32641747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eribulin mesylate in advanced breast cancer: retrospective review of a single institute experience.
    Martella F; Bacci C; Giordano C; Montagnani F; Gelain E; Rabatti L; Fioretto L
    Future Oncol; 2015; 11(15 Suppl):31-6. PubMed ID: 26235263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review on the clinical use of eribulin mesylate for the treatment of breast cancer.
    Aseyev O; Ribeiro JM; Cardoso F
    Expert Opin Pharmacother; 2016; 17(4):589-600. PubMed ID: 26809667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of eribulin mesylate in heavily pretreated breast cancer granted access via the Cancer Drugs Fund.
    Ramaswami R; O'Cathail SM; Brindley JH; Silcocks P; Mahmoud S; Palmieri C
    Future Oncol; 2014 Feb; 10(3):363-76. PubMed ID: 24367990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer.
    Goto W; Kashiwagi S; Asano Y; Takada K; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 May; 38(5):2929-2938. PubMed ID: 29715119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.